

EU Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer: Roche Diagnostics GmbH
Address: Sandhofer Strasse 116
 68305 Mannheim
 Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
Elecsys ACTH	08946710190	761333601144A5
Elecsys ACTH	08946728190	761333601145A7
Elecsys ACTH	08946728214	761333602768BQ

Intended Use:

Immunoassay for the in vitro quantitative determination of adrenocorticotrophic hormone (ACTH) in human EDTA plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
ACTH CalSet	08959820190	761333601146A9

Intended Use:

ACTH CalSet is used for calibrating the quantitative Elecsys ACTH assay on cobas e immunoassay analyzers.

Risk Class: ☐ A ☒ B ☐ C ☐ D

Conformity Route:

- ☐ Self-Declaration of Conformity (Class A)
☐ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)
☒ Technical Documentation Assessment Class B/C – Annex IX
☐ Technical Documentation Assessment Class D – Annex IX
☐ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX
☐ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX
☐ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX

Certificates:

- ☒ EU QM Certificate No.: V12 010283 0639
☐ EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):

Other:

☐ Common Specifications:

Notified Body (NB) Name:
NB Address:

TÜV Süd Product Service GmbH
Ridlerstraße 65
80339 Munich
Germany
0123


NB Ident. No.:

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 30 January 2024


Roche Diagnostics GmbH

i.V./on behalf of the company

DocuSigned by:

E3965E80F3E840E...

Dr. Christina Schmid
Head of Pre-Market Quality Core Lab

ppa./on behalf of the company

DocuSigned by:

FC5EDEC1054B44C...

Dr. Stefan Scheib
Global Head of Regulatory Affairs, Core Lab

Contact address:

Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EU Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer: Roche Diagnostics GmbH
Address: Sandhofer Strasse 116
 68305 Mannheim
 Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
Elecsys AFP	09015060190	761333602241AB
Elecsys AFP	09015086190	761333602242AD
Elecsys AFP	09015124190	761333602243AF
Elecsys AFP	09731385190	761333602956BT

Intended Use:

Immunoassay for the in vitro quantitative determination of α 1-fetoprotein in human serum and plasma.

This assay is intended for the use as:

- An aid in the diagnosis of hepatocellular carcinoma (HCC).
- An aid in the management of patients with non-seminomatous germ cell tumors.
- One component in combination with other parameters to evaluate the risk of trisomy 21 (Down syndrome).
 Further testing is required for diagnosis of chromosomal aberrations.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
AFP CalSet II	09227261190	761333602244AH

Intended Use:

AFP CalSet II is used for calibrating the quantitative Elecsys AFP assay on cobas e immunoassay analyzers.

Risk Class: ☐ A ☐ B ☒ C ☐ D

Conformity Route:

- ☐ Self-Declaration of Conformity (Class A)
- ☐ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)
- ☒ Technical Documentation Assessment Class B/C – Annex IX
- ☐ Technical Documentation Assessment Class D – Annex IX
- ☐ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX
- ☐ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX
- ☐ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX

Certificates:

☒ *EU QM Certificate No.: V12 010283 0639*
☐ *EU Technical Documentation Assessment Certificate No.*
(Class D, Near-Patient Testing, Self-Testing and Companion
Diagnostics):

Other:

☐ *Common Specifications:*

Notified Body (NB) Name:

TÜV Süd Product Service GmbH

NB Address:

Ridlerstraße 65

80339 Munich

Germany

NB Ident. No.:

0123

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 31 January 2024

Roche Diagnostics GmbH

i.V./on behalf of the company

DocuSigned by:
Christina Schmid
E3965E80F3E840E...

Dr. Christina Schmid
Head of Pre-Market Quality Core Lab

ppa./on behalf of the company

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Global Head of Regulatory Affairs, Core Lab

Contact address:

Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)

as per Annex IV of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Sandhofer Strasse 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/Product name: **Elecsys Anti-HCV II**

Art.-Nr./Cat. No.: **08836981190**
08837031190
08837058190

Beschreibung/Description: Der Elecsys Anti-HCV II Test ist ein diagnostischer In-vitro-Test für den qualitativen Nachweis von Antikörpern gegen Hepatitis-C-Virus (HCV) in Humanserum und -plasma.
Der ElektroChemilumineszenz ImmunoAssay "ECLIA" ist zur Durchführung an **cobas e** Immunoassay-Systemen vorgesehen.
The Elecsys Anti-HCV II assay is an in vitro diagnostic test for the qualitative detection of antibodies to hepatitis C virus (HCV) in human serum and plasma.
*The electrochemiluminescence immunoassay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.

to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 9 February 2022

Roche Diagnostics GmbH

ppa./on behalf of the company

DocuSigned by:

A7F0BA9FE91A46A...

Ralf Zielenski
Head Q&R Compliance, PRRC RDG
Centralised and Point of Care Solutions

ppa./on behalf of the company

DocuSigned by:

FC5EDEC1054B44C...

Dr. Stefan Scheib
Network Lead Core Lab, Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/Contact address: Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EU Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer: Roche Diagnostics GmbH
Address: Sandhofer Strasse 116
68305 Mannheim
Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
Elecsys Anti-CCP	05031656190	761333600952B5

Intended Use:

Immunoassay for the in vitro semi-quantitative determination of human IgG autoantibodies to cyclic citrullinated peptides in human serum. The results of the assay are intended to be used as an aid in the diagnosis of rheumatoid arthritis in combination with other clinical and laboratory findings.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
PreciControl Anti-CCP	05031664190	761333600953B7

Intended Use:

PreciControl Anti-CCP is used for quality control of the Elecsys Anti-CCP immunoassay on cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
Elecsys Anti-CCP	07251670190	761333600999BX

Intended Use:

Immunoassay for the in vitro semi-quantitative determination of human IgG autoantibodies to cyclic citrullinated peptides in human serum. The results of the assay are intended to be used as an aid in the diagnosis of rheumatoid arthritis in combination with other clinical and laboratory findings.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

Risk Class: ☐ A ☒ B ☐ C ☐ D

Conformity Route: ☐ Self-Declaration of Conformity (Class A)
☐ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)
☒ Technical Documentation Assessment Class B/C – Annex IX
☐ Technical Documentation Assessment Class D – Annex IX
☐ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX
☐ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX
☐ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX

Certificates: ☒ EU QM Certificate No.: V12 010283 0639
☐ EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):

Other: ☐ Common Specifications:


Notified Body (NB) Name: TÜV Süd Product Service GmbH
NB Address: Ridlerstraße 65
80339 Munich
Germany
NB Ident. No.: 0123

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 26 April 2023

Roche Diagnostics GmbH

i.V./on behalf of the company

DocuSigned by:

E3965E80F3E840E...

Dr. Christina Schmid
Head of Pre-Market Quality Core Lab

ppa./on behalf of the company

DocuSigned by:

FC5EDEEC1054B44C...

Dr. Stefan Scheib
Global Head of Regulatory Affairs, Core Lab

Contact address: Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)

as per Annex IV of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Roche Professional Diagnostics
Sandhofer Straße 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie (bei rezepturgleichen Produkten)
Roche Diagnostics GmbH declares that the product/the product line (in case of products manufactured by identical recipes)

Produktname/Product name: **PreciControl Anti-HBc IgM**

Art.-Nr./Id. No.: 11876333


Beschreibung/Description: PreciControl Anti-HBc IgM dient zur Qualitätskontrolle des Elecsys Anti-HBc IgM Immunoassays an Elecsys und **cobas e** Immunoassay-Systemen.
PreciControl Anti-HBc IgM is used for quality control of the Elecsys Anti-HBc IgM immunoassay on the Elecsys and cobas e immunoassay analyzers.

auf das/die sich diese Erklärung bezieht, den Forderungen der EG-Richtlinie 98/79/EG des Rates vom 27. Oktober 1998 (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) über In-vitro-Diagnostica entspricht.
to which this declaration relates fulfils the requirements of EC Directive 98/79/EC of the Council of 27 October 1998 (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market) concerning in-vitro diagnostic devices.

Mannheim, 21.08.2013

Roche Diagnostics GmbH
ppa./on behalf of the company i. V./on behalf of the company


Dr. M. Thein
Head of Quality
Roche Professional Diagnostics


Dr. C. Fleischer
Head of Quality Control Penzberg
Roche Diagnostics Global Operations

Kontaktadresse/Contact address: Roche Professional Diagnostics
Abt./Dept. Global Regulatory Affairs
Sandhofer Straße 116
D-68305 Mannheim
Fax: +49 621/759 1448

11876333_PreciControl Anti-HBc IgM

Roche Diagnostics GmbH Diagnostics Division

Roche Diagnostics GmbH; Werk Penzberg; Nonnenwald 2; D 82377 Penzberg; Telefon +49 8856 60 0; Telefax +49 8856 60 3896

Sitz der Gesellschaft: Mannheim - Registergericht: AG Mannheim HRB 3962 - Geschäftsführung: Thomas Schmid, Sprecher; Edgar Vieth - Aufsichtsratsvorsitzender: Dr. Severin Schwan

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)

as per Annex IV of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Sandhofer Strasse 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/Product name: **PreciControl Anti-HBc II**

Art.-Nr./Cat. No.: **04927931190**

Beschreibung/Description: PreciControl Anti-HBc II dient zur Qualitätskontrolle des Elecsys Anti-HBc II Immunoassays auf **cobas e** Immunoassay-Analysern.
*PreciControl Anti-HBc II is used for quality control of the Elecsys Anti-HBc II immunoassay on **cobas e** immunoassay analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 1 April 2022

Roche Diagnostics GmbH

ppa./on behalf of the company


DocuSigned by:

A7F0BA9FE91A46A...

Ralf Zielenski

Head Q&R Compliance, PRRC RDG
Centralised and Point of Care Solutions

ppa./on behalf of the company

DocuSigned by:

FC5EDEC1054B44C...

Dr. Stefan Scheib

Network Lead Core Lab, Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/Contact address: Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)

as per Annex IV of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/Manufacturer: Roche Diagnostics GmbH
Adresse/Address: Roche Professional Diagnostics
Sandhofer Straße 116
D-68305 Mannheim


Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie (bei rezepturgleichen Produkten)
Roche Diagnostics GmbH declares that the product/the product line (in case of products manufactured by identical recipes)

Produktname/Product name: **PreciControl Anti-HBs**
Art.-Nr./Id. No.: **11876317**
Beschreibung/Description: PreciControl Anti-HBs dient zur Qualitätskontrolle des Elecsys Anti-HBs Immunoassays an Elecsys und **cobas e** Immunoassay-Systemen.
*PreciControl Anti-HBs is used for quality control of the Elecsys Anti-HBs immunoassay on the Elecsys and **cobas e** immunoassay analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der EG-Richtlinie 98/79/EG des Rates vom 27. Oktober 1998 (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) über In-vitro-Diagnostica entspricht.
to which this declaration relates fulfils the requirements of EC Directive 98/79/EC of the Council of 27 October 1998 (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market) concerning in-vitro diagnostic devices.

Mannheim, 18.09.2012

Roche Diagnostics GmbH
ppa./on behalf of the company i. V./on behalf of the company

Dr. M. Thein
Head of Quality
Roche Professional Diagnostics
Dr. B. Rauschel
Head of Quality Control Penzberg
Roche Diagnostics Global Operations

Kontaktadresse/Contact address: Roche Professional Diagnostics
Abt./Dept. Global Regulatory Affairs
Sandhofer Straße 116
D-68305 Mannheim
Fax: +49 621/759 1448

11876317_PreciControl Anti-HBs - Ia

Roche Diagnostics GmbH Diagnostics Division

Roche Diagnostics GmbH; Werk Penzberg; Nonnenwald 2; D 82377 Penzberg; Telefon +49 8856 60 0; Telefax +49 8856 60 3896

Sitz der Gesellschaft: Mannheim - Registergericht: AG Mannheim HRB 3962 - Geschäftsführung: Thomas Schmid, Sprecher; Edgar Vieth - Aufsichtsratsvorsitzender: Dr. Severin Schwan

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)

as per Annex IV of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Sandhofer Strasse 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/Product name: **PreciControl Anti-HCV**

Art.-Nr./Cat. No.: **03290379190**

Beschreibung/Description: PreciControl Anti-HCV dient zur Qualitätskontrolle des Elecsys Anti-HCV II Immunoassays auf **cobas e** Immunoassay-Analysern.
*PreciControl Anti-HCV is used for quality control of the Elecsys Anti-HCV II immunoassay on **cobas e** immunoassay analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 1 April 2022

Roche Diagnostics GmbH

ppa./on behalf of the company

DocuSigned by:

A7F0BA9FE91A46A...

Ralf Zielenski
Head Q&R Compliance, PRRC RDG
Centralised and Point of Care Solutions

ppa./on behalf of the company

DocuSigned by:

FC5EDEC1054B44C...

Dr. Stefan Scheib
Network Lead Core Lab, Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/Contact address: Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EU Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer: Roche Diagnostics GmbH
Address: Sandhofer Strasse 116
 68305 Mannheim
 Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
PreciControl Growth	07476108190	761333600468AT

Intended Use:

PreciControl Growth is used for quality control of specified immunoassays on cobas e immunoassay analyzers.

Risk Class: ☐ A ☒ B ☐ C ☐ D

Conformity Route:

- ☐ Self-Declaration of Conformity (Class A)
- ☐ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)
- ☒ Technical Documentation Assessment Class B/C – Annex IX
- ☐ Technical Documentation Assessment Class D – Annex IX
- ☐ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX
- ☐ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX
- ☐ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX

Certificates:

- ☒ EU QM Certificate No.: V12 010283 0639
- ☐ EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):

Other: ☐ Common Specifications:

Notified Body (NB) Name: TÜV Süd Product Service GmbH
NB Address: Ridlerstraße 65
 80339 Munich
 Germany
NB Ident. No.: 0123

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 10 March 2023

Roche Diagnostics GmbH

i.V./on behalf of the company

DocuSigned by:
Christina Schmid
E3965E80F3E840E...

Dr. Christina Schmid
Head of Pre-Market Quality Core Lab

ppa./on behalf of the company

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Global Head of Regulatory Affairs, Core Lab

Contact address:

Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)

as per Annex IV of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Sandhofer Strasse 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/Product name: **PreciControl HBeAg**

Art.-Nr./Cat. No.: **11876376122**


Beschreibung/Description: PreciControl HBeAg dient zur Qualitätskontrolle des Elecsys HBeAg Immunoassays auf **cobas e** Immunoassay-Analysern.
*PreciControl HBeAg is used for quality control of the Elecsys HBeAg immunoassay on **cobas e** immunoassay analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 1 April 2022

Roche Diagnostics GmbH

ppa./on behalf of the company

DocuSigned by:

A7F0BA9FE91A46A...

Ralf Zielenski
Head Q&R Compliance, PRRC RDG
Centralised and Point of Care Solutions

ppa./on behalf of the company

DocuSigned by:

FC5EDEC1054B44C...

Dr. Stefan Scheib
Network Lead Core Lab, Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/Contact address: Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim